Richtlijn: Erfelijke darmkanker (1.0) - Genootschap van Maag-Darm ...

Richtlijn: Erfelijke darmkanker (1.0)139 - Hampel HHampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P et al. Screening for the Lynchsyndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-60.140 - Hampel HHampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin J-P et al. Cancer risk in hereditarynonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005;129:415-21.141 - Han JHan J, Kim MH. Technical review: Endoscopic papillectomy for adenomas of the major duodenal papilla.Gastrointest Endosc 2006;633:292-301.142 - Harris MAHarris MA, Byles JE. A survey of screening compliance among first degree relatives of people with coloncancer in new south wales. J Med Screen 1997;4:29-34.143 - Harris MHarris M, Winship I, Spriggs M. Controversies and ethical issues in cancer-genetics clinics. Lancet Oncol2005;6:301-10.144 - Heinimann KHeinimann K, Mullhaupt B, Weber W. Phenotypic differences in familial adenomatous polyposis based onAPC germline mutation status. Gut 1998 43:675-9.145 - Heiskanen IHeiskanen I, Kellokumpu I, Järvinen H. Management of duodenal adenomas in 98 patients with familialadenomatous polyposis. Endoscopy 1999;31:412-16.146 - Hendriks YMHendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F et al. Cancer risk inhereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.Gastroenterology 2004;27:17-25.147 - Hendriks YMCHendriks YMC, Jagmohan-Changur S, Van der Klift HM, Moreau H, Van Puijenbroek M, Tops C et al.Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).Gastroenterology 2006;130:312-22.148 - Hernegger GSHernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis. An evolving andpoorly understood entity. Dis Colon Rectum 2002;45:27-36.149 - HiguchiHiguchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind,placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polypsin familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-60.150 - Hirota WKHirota WK, Zuckerman MJ, Adler DG. ASGE Guideline: The role of endoscopy in the surveillance ofpremalignant conditions of the upper GI tract. Gastrointest Endosc 2006;63:570-80.151 - Holt WS JrHolt WS Jr. Factors affecting compliance with screening sigmoidoscopy. J Fam Pract. 1991;32:585-9.03/11/08 Erfelijke darmkanker (1.0) 97